AstraZeneca PLC
AZN
$77.53
-$0.435-0.56%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 18.14% | 10.16% | 4.49% | 34.56% | 81.11% |
| Total Depreciation and Amortization | 2.68% | 1.77% | -1.90% | -6.14% | -6.32% |
| Total Amortization of Deferred Charges | -28.57% | -4.11% | -4.11% | -4.11% | -4.11% |
| Total Other Non-Cash Items | 151.68% | 96.53% | 46.11% | 48.04% | 61.54% |
| Change in Net Operating Assets | -397.67% | -187.53% | -25.20% | -118.09% | -92.01% |
| Cash from Operations | 14.65% | 9.37% | 8.70% | -0.11% | 5.48% |
| Capital Expenditure | -41.37% | -44.12% | -44.63% | -36.82% | -24.75% |
| Sale of Property, Plant, and Equipment | -58.33% | -86.36% | -85.54% | -85.26% | -53.19% |
| Cash Acquisitions | -244.13% | -254.33% | -233.39% | -32.43% | -6.18% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -34.16% | -79.53% | -18.59% | -1.76% | -55.56% |
| Cash from Investing | -96.36% | -143.39% | -101.78% | -29.54% | -37.30% |
| Total Debt Issued | 63.24% | 96.44% | 107.57% | 63.18% | 5,274.32% |
| Total Debt Repaid | 4.05% | -6.50% | -21.99% | 8.21% | -243.89% |
| Issuance of Common Stock | 15.15% | 20.00% | 24.14% | 25.00% | 13.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -3.01% | -3.55% | -0.22% | -0.83% | -2.91% |
| Other Financing Activities | 4.11% | 8.92% | 1.46% | 1.46% | 16.33% |
| Cash from Financing | 39.15% | 45.49% | 58.58% | 50.96% | 3.75% |
| Foreign Exchange rate Adjustments | -55.00% | 56.67% | 29.35% | -15.85% | 25.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 39.88% | -142.49% | 21.70% | 292.42% | -529.09% |
